Clinical Scorecard: EYP-1901 for Retinal Exudative Diseases
At a Glance
| Category | Detail |
|---|---|
| Condition | |
| Key Mechanisms | Inhibition of VEGFR and PDGFR, and IL-6-mediated inflammatory signaling via JAK1 (source needed). |
| Target Population | |
| Care Setting |
Key Highlights
- EYP-1901 offers sustained release for at least six months after a single injection.
- Phase 2 trials showed EYP-1901 is noninferior to aflibercept in improving BCVA (source needed).
- Over 85% of EYP-1901-treated patients maintained stable or improved vision at six months (source needed).
- Phase 3 trials are ongoing for both wet AMD and DME, with topline data expected in 2026 and 2027.
Guideline-Based Recommendations
Diagnosis
Management
- Consider EYP-1901 as a treatment option in clinical trials for patients with wet AMD and DME (source needed).
Monitoring & Follow-up
Risks
Patient & Prescribing Data
EYP-1901 has shown potential for reducing treatment burden and improving vision outcomes (source needed).
Clinical Best Practices
- Utilize multi-target therapies for enhanced disease control (source needed).
- Evaluate patient response to treatment at regular intervals (source needed).
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
